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Abstract
National liver transplant volume has declined since 2006, in part due to worsening donor organ 
quality. Trends that degrade organ quality are expected to continue over the next two decades. We 
used the United Network for Organ Sharing (UNOS) database to inform a 20-year discrete event 
simulation estimating liver transplant volume from 2010 to 2030. Data to inform the model were 
obtained from deceased organ donors between 2000 and 2009. If donor liver utilization practices 
remain constant, utilization will fall from 78% to 44% by 2030, resulting in 2230 fewer liver 
transplants. If transplant centers increase their risk tolerance for marginal grafts, utilization would 
decrease to 48%. Institution of “opt-out” organ donation policies to increase the donor pool would 
still result in 1380-1866 fewer transplants. Ex-vivo perfusion techniques that increase the use of 
marginal donor livers may stabilize liver transplant volume. Otherwise, the number of liver 
transplants in the US will decrease substantially over the next 15 years.
Conclusions—The transplant community will need to accept inferior grafts and potentially 
worse post-transplant outcomes and/or develop new strategies for increasing organ donation and 
utilization in order to maintain the number of liver transplants at the current level.
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Introduction
Liver transplantation (LT) is the only effective therapy for end stage liver disease. One year 
post-LT survival is above 85%(1) compared to ∼50% one year survival for those with 
Child-Pugh C cirrhosis.(2) Unfortunately, LT as a cure for end stage liver disease is limited 
by a shortage of organ donors. Efforts to increase the donor pool have included adding 
donation after cardiac death (DCD) to standard donation after brain death (DBD).(3) 
Additionally, older donors and donors with fatty livers have been utilized in recent years.(4) 
Initial enthusiam for these additional donors has waned because the suboptimal quality of 
the livers has translated into inferior transplant outcomes in many cases.(5-9) Thus, these 
efforts to increase the total donor pool have been thwarted by higher discard rates for less 
desirable grafts .(10) Such discarding of liver grafts, often from older donors with 
nonalcoholic fatty liver disease (NAFLD) and DCD donors, is becoming more common as 
the population ages and obesity and diabetes become more prevalent.(11, 12) In addition, 
US national policies have encouraged the option of DCD, which now comprises an 
increasing portion of the donor pool.(13)
The worsening quality of donated livers and increasing discard may be negatively impacting 
LT utilization on a national level. Between 2004 and 2010, there was a 40% increase in the 
proportion of donated livers that were discarded.(10) Historically, there was steady growth 
of deceased donor LT in the US, from fewer than 2,000 performed in 1988 to over 6,300 in 
2006.(1) However, with rising discard rates, this figure has since plateaued; only 6,203 LTs 
were performed in 2013.(1) Continued increases in the prevalence of NAFLD, along with 
increasing reliance on DCD, may result in further increases in the discard rate and further 
declines in national LT volume in the future. Quantification of these anticipated trends is 
important for researchers and policymakers to identify and implement interventions to 
improve organ utilization.
Statistical forecasting models have traditionally been used to predict trends. However, when 
trends are based on causal relationships, it is not practical to build a single causal model 
accounting for all relationships among dynamic factors. Furthermore, when input factors are 
random variables (e.g. total number of organ donors), a probabilistic description of them is 
required. Standard modeling strategies such as Markov models and Monte-Carlo simulation, 
commonly used in the medical literature, lack the flexibility to adjust to changing inputs 
over time.(14) Discrete event simulation (DES) is an analytical tool typically used by 
systems engineers for evaluation of complex stochastic systems. Due to its ability to 
evaluate individuals moving through a model while concurrently considering demographic 
and health attributes, it is increasingly being used to assess health and economic outcomes in 
clinical settings, including end stage liver disease(15), organ allocation(16), colonoscopy 
performance(17), diabetes care(18), and rheumatologic disease(19) among others. 
Furthermore, DES allows for dynamic and probabilistic changes in external factors, such as 
phased policy changes, that may impact individuals differentially. Because the factors that 
influence donor liver discard change over time, DES can allow for more accurate estimates 
of future organ availability. We therefore used DES to simulate the future of adult deceased 
donor LT in the US and considered several scenarios that might impact liver utilization.
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Methods
Overview
We used the United Network for Organ Sharing (UNOS) database to build a DES model to 
forecast liver donor characteristics, liver discard, and LT volume over a twenty year period. 
The model was informed by data from 2000 to 2009 to create predictions from 2010 to 2030 
using Arena version 15 (Rockwell Automation, Milwaukee, WI). Available data from 2010 
and 2011 were not included in model derivation, but were instead reserved for validation. 
Because of systematic differences between the organ donor population and the general 
population, other population-based data sources were evaluated, but not used. Full details of 
the DES model construction have been reported previously.(20)
Outcome
The primary outcome of the simulation was the proportion of donated livers used for 
transplantation annually from 2010 to 2030.
Inclusion/Exclusion Criteria
We used the UNOS database to derive the input data for the DES model. We included all 
deceased adult (age ≥ 18) solid organ donors who had at least one organ (liver, heart, 
intestine, kidney, lung, or pancreas) transplanted into a recipient between 2000 and 2009. 
This group was chosen because it lacks an absolute contraindication to organ donation in 
general (e.g. HIV), and therefore liver discard would likely be specifically due to poor liver 
quality. Split liver donations and those with extreme body mass index (BMI) were also 
excluded as previously described. (10, 20)
DES Model Construction
Important variables of interest were donor age, gender, race/ethnicity (non-Hispanic white, 
non-Hispanic black, or Hispanic), obesity (BMI ≥ 30 kg/m2), diabetes, alcohol use (≥ 2 
drinks per day), alanine transaminase (ALT), bilirubin, cause of death, and DCD. These 
variables were selected due to their impact on donor liver discard. (10, 20) The independent 
odds ratios of discard based on these factors are shown in Figure 1. The DES donor 
generator produced a simulated donor starting with gender and, based on this, would assign 
an age and race. From these demographics, obesity, diabetes, alcohol use, and stroke would 
be assigned using the relationships discovered among the variables adjusted for the passage 
of time (e.g. the likelihood of diabetes as a function of age changes with each passing year 
and is dependent on obesity). Mild-to-moderate elevation of ALT in the absence of other 
liver disease may reflect NAFLD (21) whereas more severe elevations are likely due to 
acute donor illness. ALT was therefore assigned using nested logistic regression, including 
NAFLD risk factors of age, obesity, and diabetes for elevations up to 200 U/L, with higher 
ALT elevations modeled on age (with and without diabetes) adjusted for time.(20) Total 
bilirubin and DCD were not found to be dependent on other factors and thus assigned 
independently based on historic time dependent trends. The rationale and modeling for the 
donor generator has been previously described.(20) The relationships among variables and 
flow of the simulated variable dependencies are shown in Figure 1. Based on the 
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characteristics of the simulated donor, the probability of organ discard was calculated. The 
simulator performed 15 replications of 100,000 donors in order to create an annual forecast 
for years 2010-2030. As a result of the number of donors and replications, the 95% 
confidence intervals for all of the estimates were within +/- 0.01% of the mean values 
shown, and were therefore suppressed in the results. (20)
Validation
Data were gathered from 2000 to 2009 to inform the DES model with available data from 
2010 and 2011 withheld. Once the model was constructed, validity was assessed by 
comparing model derived data to actual historical data (Table 1). Overall, the estimation 
error was at or below 2% of the historical data for all variables.
Baseline Model: Donor Characteristics 2010-2030
The baseline model assumes that the previous population trends of obesity and diabetes in 
organ donors will continue unchanged in the future, and that the use of DCD will continue to 
increase as it has in previous years. This model provides the baseline data for donor liver use 
over a 20 year period and has been reported previously in a description of the simulation 
methodology.(20) We estimate the proportion of donors aged ≥ 50 will increase from 39.2% 
in 2010 to 43.7% in 2030 (Table 2). The prevalence of diabetes among organ donors is 
projected to increase from 13.8% to 45.7%, and the prevalence of obesity (BMI ≥ 30 kg/m2) 
will increase from 31.2% to 58.2%. Donors with an abnormal ALT (> 40 U/L) will increase 
from 44.5% to 60.9%. Overall, liver utilization will fall from 77.9% in 2010 to 43.6% in 
2030, if current utilization practices remain constant. Therefore, for a static donor population 
of 6500, the current trends of DCD procurement, the aging donor population, and increases 
in diabetes and obesity among donors will result in 2,230 fewer LTs per year by 2030. These 
data are summarized in Table 3. Figure 2 illustrates the forecasted number of liver 
transplants performed in 2030 based on a donor population that grows with the census 
population with the other assumptions of the baseline scenario.
Scenario Analyses
In addition to the previously published baseline model, we considered plausible scenarios 
that might alter these trends or change the risk of liver discard.
Scenario 1 acknowledges the potential for greater programmatic risk tolerance and organ 
utilization as a direct response to shrinking volumes. Some regions utilize more expanded 
criteria donors and have non-use rates below the national mean.(10, 22) This scenario 
increases the “aggressiveness” to which all centers and regions pursue marginal grafts and 
increases utilization by 10%. This increased utilization is phased into clinical practice in 
2015 according to an S-shaped diffusion of innovation curve.(23)
Scenario 2 considered an organ procurement policy change that muted the detrimental 
impact of DCD on LT volume. This scenario assumes that a portion of DCD donors would 
have progressed to brain death if given more time, and that such a conversion of DBD to 
DCD explains in part the recent rapid increase in DCD. Although controversial, this 
possibility is supported by data demonstrating concurrent decreases in DBD with increasing 
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DCD.(24, 25) In scenario 2, we assumed an implementation of policies discouraging DCD, 
with an associated “reverse” conversion of DCD to DBD. In 2a, we estimated this 
conversion to occur for between 5 to 20% of donors, using a triangular distribution. A 
second iteration of this scenario (2b) was run with the assumption of a profound shift in 
policy, converting 90% of DCD to DBD, virtually eliminating DCD as a procurement 
strategy.
Scenario 3 considers a disruptive technological change in regard to ex vivo reperfusion (i.e. 
“pumping”) of donor organs that might mitigate the non-use of marginal grafts from older 
donors and donors with diabetes, obesity or DCD. This technology was applied to all 
donated grafts where more marginal grafts would receive a proportionately greater benefit in 
utilization than grafts that had a greater probabilistic chance of being accepted and utilized. 
As in the other scenarios, this change was introduced in 2015 using a diffusion of innovation 
curve. Relative reduction in graft discard was calculated across a range from 20-90% and 
applied to the model.
Scenario 4 adjusted the total population of donors. Static increases of 1-4% per annum were 
investigated as well as specific strategies for increasing donation such as opt-in versus opt-
out policies for organ donation. For the use of opt-out donation policies, a range for the 
change in total number of additional donors was derived from the literature(26-30) and 
incorporated into the simulation as a onetime increase in donors using an innovation 
diffusion curve.(23) Risks for organ discard remained static in this simulation.
The scenario analyses made changes independently; changes in one scenario were set to the 
baseline for other scenarios. This allowed for examination of the effects of single changes. 
Combination of scenarios 1-3 were not performed to avoid double counting donors and 
falsely adjusting liver discard.
Results
Scenario 1: Increasing risk tolerance and organ utilization
We performed a simulation where organ utilization increased by 10% from 2015 to 2025 
according to a diffusion curve. In 2025, after these behavioral changes had completely taken 
effect, organ utilization was 58%, but fell to 48% by 2030 due to ongoing worsening of 
donor comorbidities. This scenario demonstrated a 4.4% increase in overall liver graft 
utilization over the baseline scenario by 2030.
Scenario 2: Policy to Reduce DCD
In scenario 2, we simulated the impact of a procurement policy change in 2015 that 
discouraged DCD and encouraged DBD donation, assuming that a proportion of DCD 
donors can progress to brain death. Initially, we performed a conservative simulation that 
converted 5 to 20% of DCD donors to DBD (specified using a triangular distribution). This 
intervention resulted in the conversion of 237 DCD livers to DBD (assuming a static donor 
population of 6500) and increased utilization by 1.7% to 45.3% by 2030. A more dramatic 
assumption where 90% of DCD donors are converted to DBD increased utilization by 
13.4% to 57.0% by 2030, the highest level seen in any simulation.
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Scenario 3: Disruptive technology change with ex vivo perfusion of all grafts
Scenario 3 examines ex vivo perfusion of all grafts with greater proportionate benefit to the 
most marginal grafts which are more likely to be those that come from older, diabetic donors 
and DCD. A range of relative reduction in non-use was considered from 20-90%. With such 
a technology, implemented in 2015 with a stable donor pool, utilization rates would increase 
from the baseline scenario to 82-98% yielding a liver transplant volume of 5,351 – 6,356. 
Applied over time, “pumping” of livers would result in a utilization rate between 55-95% in 
2030 for a volume of 3567-6191 transplants. A comparison of all utilization scenarios is 
shown in Table 3.
Scenario 4: Expanding the donor population
Increasing the donor pool by 1% annually would increase the number of potential donors 
from 6,500 to 7,931 by 2030. A 3% annual increase would result in 11,740 donors by 2030. 
A 4% per annum increase would yield 14,242. Matching the growth of the donor pool to 
population growth data from the US census yields 7,536 donors by 2030. With 43.6% 
utilization in 2030, a 3-4% per annum increase would allow the total number of liver 
transplants to remain stable. Organ donation “opt-out” policies assume as a default that 
people are organ donors and require active participation to opt out of donation. Such policies 
have been shown to increase the number of donors by from 2.7 per million population to 
30%, depending on the study population.(26-30) Extrapolating from the US population, such 
a policy would increase the absolute number of organ donors somewhere between 834 and 
1950 donors. In a more optimistic assumption of a 90% increase in the donor pool due to 
opt-out policy, transplant volume would remain relatively stable. The effects of various 
strategies to increase the total donor pool are summarized in Table 4.
Discussion
According to these simulations, the number of deceased donor liver transplants (LT) done 
will decrease considerably through 2030 due to worsening donor liver quality and 
consequent increasing organ discard. In 2010, 5,064 out of 6,500 potential livers were 
transplanted for a utilization rate of 78%. Increases in donor age, obesity, diabetes and 
donation after cardiac death (DCD) will combine to decrease utilization to 44% by 2030. 
Without a disruptive technological change or a significant increase in the total number of 
organ donors, the number of liver transplants performed in the United States may fall 
substantially.
In addition to this baseline simulation, we examined several scenarios that incorporated 
changing behaviors, procurement policies and donor health attributes. While all adjustments 
to the model increased utilization, only two increased the utilization rate by more than 5% 
over the 2030 baseline model: (1) converting 90% of DCD donors to standard DBD and (2) 
an innovative technological change with ex vivo perfusion that allows pumping of all grafts. 
These adjustments improved 2030 utilization projections, but total utilization will still 
remain lower than current levels unless the most optimistic projections come to fruition. 
Increase in overall donation could mitigate the effect of lower utilization, but the increase in 
donation would have to be 3-4% per year which is unrealistic based on current donation 
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trends. Increasing the “aggressiveness” of centers when utilizing marginal donors yields 
only a marginal increase in the overall number of liver transplants performed at an untold 
cost of worsening post-transplant outcomes.
DCD has been emphasized as a strategy to increase the organ donor pool as a part of the 
Organ Donation Breakthrough Collaborative.(13) As experience with DCD grafts has 
grown, the LT community has seen inferior outcomes with DCD grafts(9) and consequently 
a higher discard rate of these livers.(10) The deleterious impact of DCD may not be so 
evident in other fields of organ transplantation, especially kidney transplant,(31-33) thus 
setting up a potential conflict between increasing the total number of donor kidneys and 
maintaining the quality of donor livers. Many in the liver transplant community have been 
concerned that DCD has not added to the total donor pool, but has instead eroded into the 
donation after brain death (DBD) population resulting in no net gain of organ donors.(10) 
Since 2006, the total number of donated livers has remained stagnant, while the proportion 
of DCD donors has steadily increased from ∼1% to 12.5% in 2010.(10) Similar trends have 
been described in Europe.(34) If these trends continue, our projections estimate the 
proportion of DCD donors could reach 36% by 2030. The possibility of DCD displacing 
DBD is further supported by a multinational study that found that countries with higher 
DCD rates have lower DBD rates.(25)
Increasing the rate of organ, tissue and eye donation has long been the goal of multiple 
organizations including the U.S. Department of Health Resources and Service 
Administration's Workplace Partnership for Life campaign, the Donate Life America 
alliance and the American Hospital Association. Unfortunately, these organizations would 
need to significantly increase donations to meet simulated demand. Relying on living donor 
liver transplantation is unlikely to completely fill the void created by older, obese or diabetic 
cadaveric donors. Thresholds for steatosis are much lower among living donor grafts(35) 
and the epidemics of diabetes and obesity will impact this population as well. Even now, 
only a minority of liver failure patients has an appropriate living donor who qualifies for 
right lobe donation.(36) The ability to identify suitable living donors depends on multiple 
factors beyond donor comorbidities and procurement strategies, including transplant center, 
family dynamics, social factors and donor consent that are beyond the scope of the current 
simulation.
Major technological advances, such as the advent of an ex-vivo perfusion technique that is 
widely accessible enough to allow back table pumping of all grafts, might change this 
otherwise dreary forecast. An innovative technology that mitigates the risk of non-use 
among older, diabetic and obese donors as well as DCD may be the only avenue for 
sustaining the current level of liver transplantation. This technology, and even the concept of 
organ assessment and repair centers, is under development currently and had shown benefit 
in markers of cell death and regeneration, but has yet to fully make the leap from bench to 
bedside. (37-40) While not simulated, an additional benefit of ex vivo graft perfusion could 
also include expanded cold ischemia time and a wider geographic range for graft sharing.
Three dimensional bio-printing is another potentially disruptive technology that could 
eliminate the need for organ donors entirely. Bio-printing builds functional biological tissue 
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over a biological scaffold and holds the potential to meet the need for organ 
transplantation(41). This technology is in its infancy, however, and the ability of bio-
printing to solve the organ donor crisis when even extracorporeal liver support systems have 
yet to be realized remains controversial.
The strengths of our simulation include a rich data source, the UNOS donor database, on 
which to base our simulation. The UNOS donor data, particularly for age, BMI, DCD, 
diabetes and hypertension, are probably quite accurate because they are collected over a 
relative brief period of time by professional procuring teams who understand how critical 
such data are for proper organ disposition. Withholding data from 2010 and 2011 in 
construction of the DES allowed model validation. We found our model estimated all 
variables to 2% or closer to actual known values. Compared to other forecasts of future liver 
diseases, such as HCV (42), our estimates appear to be more accurate likely due to the DES 
methodology that allows for more complex modeling over prolonged time horizons.(14)
With any long term forecast of future disease, there can always be unanticipated 
developments that alter predictions. New technologies, changes in medical care, or 
substantial shifts in transplant and/or organ procurement policy may render these 
simulations less accurate. We have tried to account for these events through our various 
scenarios but we could not model on all possible changes in demographics and policy that 
could occur simultaneously. Furthermore, we were unable to model combinations of 
scenarios (e.g. ex-vivo perfusion and opt-out donation together). Such combinations of 
technological advances with policy changes in response to this potential crisis may actually 
be more likely than individual changes and would be more likely to preserve transplant 
volumes. Nevertheless, even if our models' estimates are too pessimistic by 50%, these data 
are alarming as the total number of liver transplants will still fall significantly below current 
levels while the burden of end stage liver disease (ESLD) from HCV and NAFLD is only 
expected to increase over this time period.(42, 43)
The liver transplant community and general public face a choice between accepting lower 
quality organs with the possibility of inferior post-transplant outcomes, or continuing current 
practices at the expense of increased mortality for patients on the waiting list. Reductions in 
liver transplant volume will result in increased numbers of patients waiting for transplant, 
longer waitlist times and higher Model of End-Stage Liver Disease scores at the time of 
transplant. Each of these events will likely lead to an increase in complications of ESLD, 
longer post transplant hospitalizations, and overall increased healthcare costs.
The complications of ESLD are expensive, and as patients wait longer for transplant, these 
episodes will become more common. In 2008 dollars, complicated variceal bleeding 
hospitalization mean costs were $23,207 with a mean length of stay of 15 days.(44) Over a 
five year period from 2005 to 2009, inpatient charges for hepatic encephalopathy rose from 
$46,663 to $63,108 per case leading to a national increase in encephalopathy related 
inpatient spending from 4.7 billion to 7.2 billion.(45) During the same time period, HCC 
related inpatient charges rose from $29,466 to $31,656 per case for an overall national 
spending increase from 1.0 billion to 2.0 billion.(46) These complications may occur 
repeatedly while patients wait for a transplant.
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Increased MELD at the time of transplant and increased donor comorbidities have been 
shown to increase transplant related costs and the combination of these two factors is 
synergistic.(47) Donors in the highest risk quartile of the Donor Risk Index add $12,000 to 
the cost of transplant and another $22,000 to post transplant costs, relative to low risk 
donors, pushing overall one year costs to over $200,000 in 2008 U.S. dollars. DCD donors 
increased costs by $21,000 over standard donation after brain death (DBD) donors.(47) 
These costs are directly attributable to longer post transplant hospital stays associated with 
increasing donor comorbidities. (48)
Our model suggests a dire forecast for the future of liver transplantation that has major 
implications for the increasing number of patients suffering from liver failure. National 
epidemics of diabetes and obesity will increase the number of patients with NAFLD related 
liver failure,(49) while at the same time compromising the quality of donated livers for all 
indications for liver transplantation. The use of new technology for organ preservation, 
living donation and increasing the donation rate may slow the decline but not arrest it. 
Accepting worse outcomes by using worse organs may be the only way to maintain organ 
utilization rates. Whether this can be done in a cost-effective manner based on quality of life 
years saved is unclear.
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Figure 1. 
DES simulation framework. Dependent variable relationships, represented by lines, modeled 
via logistic regressions using UNOS data. Shaded variables are also dependent on the 
passage of time. 100,000 potential donors simulated with 15 replications for each scenario. 
Odds ratios adapted from Orman, et al10, from prior work in UNOS database and used to 
inform model.
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Figure 2. 
Using a population based estimate, the total number of donors will increase by 2030, but the 
corresponding increases in DCD, donor obesity and diabetes will increase the discard rate 
and reduce the total number of adult whole liver transplants over the next 20 years
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Table 1
DES Model Validation: Actual and Predicted Donor Characteristics: 2010
Characteristic 2010
(Actual)
2010
(Predicted)
Age
 < 30, % 24.6 23.7
 30-39, % 15.9 14.4
 40-49, % 21.7 22.6
 50-59, % 22.6 23.6
 ≥ 60, % 15.2 15.7
Sex, % male 58.9 58.7
Race/ethnicity
 White, % 69.2 68.1
 Black, % 16.8 17.0
 Hispanic, % 14.1 15.0
Obese, % 30.7 31.2
Alcohol use, % 17.9 18.8
Diabetes, % 12.0 13.8
Stroke, % 40.8 43.0
DCD, % 11.4 12.5
Bilirubin, mg/dL
 ≤ 1.2, % 76.2 73.7
 1.3-2.5, % 18.4 21.0
 2.6-5.0, % 4.1 4.1
 > 5.0, % 1.4 1.3
ALT, U/L
 ≤ 40, % 56.1 55.5
 41-200, % 36.4 36.5
 201-400, % 4.0 3.8
 > 400, % 3.5 4.2
Liver discard, % 20.5 22.1
The DES model was created by UNOS data from 2000-2009. Available data from 2010 were withheld from model construction and used for 
validation.
Liver Transpl. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Orman et al. Page 16
Ta
bl
e 
2
Se
le
ct
ed
 a
ttr
ib
ut
es
 o
f l
iv
er
 d
on
or
 p
op
ul
at
io
n 
20
10
-2
03
0
M
al
e
A
ge
 >
=5
0 
yr
s.
W
hi
te
Bl
ac
k
H
isp
an
ic
A
lc
oh
ol
 U
se
O
be
se
 (B
M
I>
30
 kg
/m
2)
D
ia
be
tic
D
C
D
A
bn
or
m
al
 A
LT
Y
ea
r
%
20
10
58
.8
39
.2
68
.2
16
.9
14
.9
18
.8
31
.2
13
.8
12
.5
44
.5
20
15
58
.8
40
.3
63
.8
19
.8
16
.5
18
.9
38
.0
19
.7
18
.4
48
.7
20
20
58
.7
41
.3
59
.4
22
.5
18
.1
18
.9
45
.0
27
.2
24
.3
52
.8
20
25
58
.7
42
.6
55
.0
25
.3
19
.7
19
.0
51
.8
36
.1
30
.2
56
.9
20
30
58
.7
43
.7
50
.7
28
.0
21
.3
19
.0
58
.2
45
.7
36
.1
60
.9
Liver Transpl. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Orman et al. Page 17
Ta
bl
e 
3
Pr
op
or
tio
n 
of
 li
ve
r 
gr
af
ts
 su
ita
bl
e 
fo
r 
tr
an
sp
la
nt
at
io
n 
an
d 
fo
re
ca
st
ed
 n
um
be
r 
fo
r 
ad
ul
t o
rt
ho
to
pi
c 
liv
er
 tr
an
sp
la
nt
s p
er
fo
rm
ed
 b
as
ed
 o
n 
cu
rr
en
t o
rg
an
 d
on
at
io
n 
tr
en
ds
Sc
en
ar
io
20
10
20
15
20
20
20
25
20
30
u
til
iz
at
io
n
ra
te
 (%
)
tr
an
sp
la
nt
s
u
til
iz
at
io
n
ra
te
 (%
)
tr
an
sp
la
nt
s
u
til
iz
at
io
n
ra
te
 (%
)
tr
an
sp
la
nt
s
u
til
iz
at
io
n
ra
te
 (%
)
tr
an
sp
la
nt
s
u
til
iz
at
io
n
ra
te
 (%
)
tr
an
sp
la
nt
s
B
as
el
in
e 
M
od
el
77
.9
50
64
70
.1
45
57
61
.6
40
04
52
.6
34
19
43
.6
28
34
In
cr
ea
se
d 
ag
gr
es
siv
en
es
s
1
77
.9
50
64
70
.2
45
60
64
.0
41
62
57
.9
37
61
48
.0
31
17
Ch
an
ge
s i
n 
or
ga
n 
pr
oc
ur
em
en
t p
ol
ic
y
2a
77
.9
50
64
70
.1
45
57
62
.1
40
37
54
.2
35
23
45
.3
29
45
2b
77
.9
50
64
70
.2
45
63
65
.5
42
58
64
.4
41
86
57
.0
37
05
Ex
 v
iv
o 
pe
rfu
sio
n
3(2
0%
-90
% 
red
uc
tio
n i
n u
nu
sed
 gr
aft
s)
82
.3
-9
7.
8
53
51
-6
35
6
76
.1
-9
6.
9
49
45
-6
30
6
69
.3
-9
6.
2
45
03
-6
25
0
62
.1
-9
5.
7
40
35
-6
22
0
54
.9
-9
5.
2
35
67
-6
19
1
Th
is 
ta
bl
e 
sh
ow
s t
he
 p
ro
po
rti
on
 o
f l
iv
er
 g
ra
fts
 a
pp
ro
pr
ia
te
 fo
r a
du
lt 
w
ho
le
 li
ve
r o
rth
ot
op
ic
 tr
an
sp
la
nt
 b
y 
fiv
e 
ye
ar
 in
te
rv
al
s f
ro
m
 2
01
0 
th
ro
ug
h 
20
30
 a
m
on
g 
do
no
rs
 w
ho
 w
er
e 
ab
le
 to
 su
cc
es
sf
ul
ly
 d
on
at
e 
at
 le
as
t o
ne
 o
rg
an
. S
ce
na
rio
 c
ha
ng
es
 a
re
 in
se
rte
d 
in
to
 th
e 
m
od
el
 st
ar
tin
g 
in
 
20
15
 w
ith
 a 
te
n 
ye
ar
 d
iff
us
io
n 
of
 in
no
va
tio
n 
cu
rv
e. 
N
um
be
r o
f t
ot
al
 d
on
or
s s
et
 at
 6
50
0 
ba
se
d 
on
 d
at
a f
ro
m
 2
00
6-
20
10
.
In
 sc
en
ar
io
 1
, o
rg
an
 u
til
iz
at
io
n 
is 
in
cr
ea
se
d 
by
 1
0%
 fr
om
 2
01
5 
to
 2
02
5 
us
in
g 
a d
iff
us
io
n 
cu
rv
e
In
 sc
en
ar
io
 2
a,
 5
-2
0%
 o
f D
CD
 d
on
or
s a
re
 co
nv
er
te
d 
to
 D
BD
 d
on
or
s u
sin
g 
tri
an
gu
la
r d
ist
rib
ut
io
n,
 in
 2
b,
 9
0%
 o
f D
CD
 d
on
or
s a
re
 co
nv
er
te
d 
to
 D
BD
 d
on
or
s
In
 sc
en
ar
io
 3
, e
x 
vi
vo
 p
er
fu
sio
n 
of
 a
ll 
gr
af
ts 
is 
ex
am
in
ed
. A
 ra
ng
e 
of
 re
la
tiv
e 
re
du
ct
io
n 
in
 n
on
-u
se
 w
as
 c
on
sid
er
ed
 fr
om
 2
0-
90
%
.
Liver Transpl. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Orman et al. Page 18
Ta
bl
e 
4
Ex
pa
nd
in
g 
th
e 
to
ta
l o
rg
an
 d
on
or
 p
op
ul
at
io
n
St
ra
te
gy
/A
ss
um
pt
io
n
20
10
20
15
20
20
20
25
20
30
D
on
or
s
Tr
an
sp
la
nt
s
D
on
or
s
Tr
an
sp
la
nt
s
D
on
or
s
Tr
an
sp
la
nt
s
D
on
or
s
Tr
an
sp
la
nt
s
D
on
or
s
Tr
an
sp
la
nt
s
St
at
ic
 D
on
or
 p
op
ul
at
io
n 
G
ro
w
th
1%
 a
nn
ua
l g
ro
w
th
6,
50
0
50
64
6,
83
2
47
89
7,
18
0
44
23
7,
54
6
42
41
7,
93
1
34
58
2%
 a
nn
ua
l g
ro
w
th
6,
50
0
50
64
7,
17
7
50
31
7,
92
3
48
81
8,
74
8
49
16
9,
65
9
42
11
3%
 a
nn
ua
l g
ro
w
th
6,
50
0
50
64
7,
53
5
52
82
8,
73
5
53
81
10
,1
27
56
91
11
,7
40
51
19
4%
 a
nn
ua
l g
ro
w
th
6,
50
0
50
64
7,
90
8
55
43
9,
62
2
59
27
11
,7
06
65
79
14
,2
42
62
10
D
on
or
 p
op
ul
at
io
n 
lin
ke
d 
to
 C
en
su
s
Ce
ns
us
 p
ro
jec
tio
n
6,
50
0
50
64
6,
75
6
47
36
7,
01
9
43
24
7,
28
2
40
92
7,
53
6
32
86
In
te
rn
at
io
na
l o
pt
 o
ut
 d
on
at
io
n 
st
ra
te
gy
 e
sti
m
at
io
ns
A
ba
di
e 
et
 a
l(3
0)
6,
50
0
50
64
6,
51
6
45
68
7,
27
2
44
80
8,
45
0
47
49
8,
45
0
36
84
N
et
o 
et
 a
l(3
3)
6,
50
0
50
64
6,
51
1
45
64
7,
04
0
43
37
7,
86
5
44
20
7,
86
5
34
29
H
ea
ly
 e
t a
l(3
2)
6,
50
0
50
64
6,
50
7
45
61
6,
83
0
42
07
7,
33
4
41
22
7,
33
4
31
98
G
im
be
l e
t a
l(3
1)
6,
50
0
50
64
6,
51
5
45
67
7,
25
0
44
66
8,
39
6
47
19
8,
39
6
36
61
U
ni
ve
rs
al
 o
pt
 o
ut
 st
ra
te
gy
90
%
 o
f e
lig
ib
le
 
po
pu
la
tio
n 
do
na
te
6,
50
0
50
64
6,
54
7
45
89
8,
81
5
54
30
12
,3
50
69
41
12
,3
50
53
85
Ta
bl
e 
4 
su
m
m
ar
iz
es
 th
e 
to
ta
l n
um
be
r o
f o
rg
an
 d
on
or
s w
ho
 su
cc
es
sf
ul
ly
 d
on
at
e 
at
 le
as
t o
ne
 o
rg
an
 p
en
di
ng
 c
ha
ng
es
 in
 v
ar
io
us
 d
on
at
io
n 
str
at
eg
ie
s.
To
ta
l l
iv
er
 tr
an
sp
la
nt
s p
er
fo
rm
ed
 c
al
cu
la
te
d 
ba
se
d 
on
 u
til
iz
at
io
n 
ra
te
s f
ro
m
 b
as
el
in
e 
as
su
m
pt
io
ns
 in
 sc
en
ar
io
 1
.
In
 o
rd
er
 to
 k
ee
p 
pa
ce
 w
ith
 th
e 
cu
rre
nt
 n
um
be
r o
f l
iv
er
 tr
an
sp
la
nt
s p
er
fo
rm
ed
, t
he
re
 n
ee
ds
 to
 b
e 
ap
pr
ox
im
at
el
y 
3%
 p
er
 y
ea
r g
ro
w
th
 in
 th
e 
do
no
r p
op
ul
at
io
n 
or
 a
 u
ni
ve
rs
al
 o
pt
 in
 o
rg
an
 d
on
or
 st
ra
te
gy
Liver Transpl. Author manuscript; available in PMC 2016 August 01.
